Pfizer (NYSE:PFE) Stock Price Down 1.3% – Here’s What Happened

Pfizer Inc. (NYSE:PFE) traded down 1.3% during mid-day trading on Tuesday . The stock traded as low as $24.69 and last traded at $24.75. 81,903,066 shares were traded during mid-day trading, an increase of 97% from the average session volume of 41,572,313 shares. The stock had previously closed at $25.08.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA expanded Pfizer’s Ibrance label for maintenance treatment in HR-positive, HER2-positive advanced or metastatic breast cancer, giving the company a fresh commercial boost in oncology. FDA expands Pfizer’s Ibrance label for frontline maintenance in advanced breast cancer
• Positive Sentiment: Pfizer also announced a quarterly dividend of $0.43 per share, reinforcing its shareholder-return profile and signaling continued cash-generation discipline. Pfizer Declares Third-Quarter 2026 Dividend
• Positive Sentiment: The dismissal of Pfizer from a U.S. states’ generic drug price-fixing lawsuit removes a legal overhang that had been hanging over the stock. Pfizer dismissed from US states’ drug price-fixing lawsuit
• Neutral Sentiment: Pfizer Ventures led a $62 million Series B round for Oblenio Bio, highlighting the company’s venture investment activity, but the news is not likely to move shares materially on its own. Oblenio Bio Closes $62 Million Series B
• Negative Sentiment: Investor sentiment was hurt by Pfizer’s mixed Phase 3 oncology update, especially the failed overall survival result in its lung cancer program, which appears to be outweighing the Ibrance win for now. Pfizer (PFE) Is Down 7.3% After Mixed Oncology Updates Reshape Its Long-Term Pipeline Narrative

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Morgan Stanley raised their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a research report on Tuesday. Guggenheim lifted their price objective on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research note on Tuesday, March 24th. Wolfe Research reiterated an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a report on Thursday, May 14th. Finally, CICC Research assumed coverage on Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $28.82.

Pfizer Price Performance

The firm has a market cap of $135.45 billion, a price-to-earnings ratio of 18.14 and a beta of 0.34. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The company has a 50 day moving average of $26.07 and a 200 day moving average of $26.31.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm had revenue of $14.45 billion during the quarter, compared to analysts’ expectations of $13.84 billion. During the same period in the previous year, the firm earned $0.92 earnings per share. The company’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts predict that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s dividend payout ratio is presently 131.30%.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its position in Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after acquiring an additional 7,031,162 shares in the last quarter. State Street Corp increased its holdings in Pfizer by 0.5% during the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after purchasing an additional 1,357,756 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Pfizer by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 130,192,081 shares of the biopharmaceutical company’s stock valued at $3,235,642,000 after purchasing an additional 1,184,728 shares during the period. Morgan Stanley lifted its holdings in shares of Pfizer by 19.2% in the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock valued at $2,218,929,000 after purchasing an additional 14,342,946 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Pfizer during the fourth quarter worth about $1,830,986,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.